Clinical Data on a Preventive Migraine Treatment

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinical Data on a Preventive Migraine Treatment

Program Information

Program Information

ReachMD Healthcare Image

Learn more about the clinical data for a preventive treatment option for migraine.

  • Overview

    Learn more about the efficacy and other clinical data for this preventive migraine treatment option. Dr. Brad Torphy highlights clinical data on this treatment option. 


    AJOVY® (fremanezumab-vfrm) injection is indicated for the preventive treatment of migraine in adults. 


    Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

    Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

    Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.

    Please see the full Prescribing Information for AJOVY.

    Sponsored by Teva Pharmaceuticals USA, Inc. FRE-44406 | Mobile: FRE-44429  12/22

Schedule8 Feb 2023